CPT Code Overview

CPT code 81434 is used for genetic testing related to hereditary breast cancer disorders. This code covers a genomic sequence analysis panel that must include sequencing of at least 14 genes, such as ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, and TP53. The typical site of service for this procedure is a laboratory setting (POS 81). This test is essential for identifying genetic susceptibility to breast and ovarian cancer, supporting clinical decision-making for patients with a family history or risk factors for these conditions.

Clinical Context

A patient with a personal or family history of breast or ovarian cancer is referred for genetic testing to assess hereditary risk. The ordering provider, often a medical geneticist or oncologist, requests a comprehensive genomic sequence analysis panel to evaluate mutations in at least 14 genes associated with hereditary breast cancer-related disorders. The specimen is collected and sent to a laboratory (Place of Service 81) specializing in genetic testing. Results inform clinical management, risk assessment, and potential preventive strategies for the patient and their relatives.

Coding Specifications

• Modifiers:

  • Modifier 26: Used when reporting only the professional component of the genetic testing service, such as interpretation of results by a qualified provider.
  • Modifier 59: Indicates a distinct procedural service, used when the genetic testing is performed separately from other procedures.

• Provider Taxonomies:

  Taxonomy Code	Specialty Name
  207SG0201X	Medical Genetics, Ph.D. Medical Genetics
  207SC0300X	Medical Genetics, Clinical Genetics (M.D.)
  207SG0202X	Medical Genetics, Clinical Biochemical Genetics
  207SG0203X	Medical Genetics, Clinical Cytogenetics
  207SG0205X	Medical Genetics, Clinical Molecular Genetics

These specialties represent providers qualified to order, interpret, and manage genetic testing for hereditary breast cancer-related disorders.

Related Diagnoses

• Z15.01: Genetic susceptibility to malignant neoplasm of breast

  • Indicates a patient has a genetic predisposition to breast cancer, supporting the need for hereditary cancer panel testing.

• C50.919: Malignant neoplasm of unspecified site of unspecified female breast

  • Used when a patient has a diagnosis of breast cancer, which may prompt genetic testing to assess hereditary risk.

• Z80.3: Family history of malignant neoplasm of breast

  • Documents a family history of breast cancer, a key factor in determining eligibility for genetic testing.

• Z80.41: Family history of malignant neoplasm of ovary

  • Indicates family history of ovarian cancer, relevant due to shared genetic risk factors with breast cancer.

• Z84.81: Family history of carrier of genetic disease

  • Used when there is a family history of being a carrier for genetic diseases, supporting the rationale for comprehensive genetic testing.

Related CPT Codes

• 81211: BRCA1, BRCA2 gene analysis

  • Used for targeted analysis of BRCA1 and BRCA2 genes, often as an initial test or when only these genes are clinically indicated.

• 81213: BRCA1, BRCA2 gene analysis, full sequence

  • Provides comprehensive sequencing of BRCA1 and BRCA2, used when a more detailed analysis is required.

• 81432: Hereditary breast cancer-related disorders, genomic sequence analysis panel

  • Similar to 81434, but may differ in the number of genes analyzed or panel composition. Used as an alternative or in conjunction with 81434 depending on clinical needs.

• 81433: Hereditary breast cancer-related disorders, duplication/deletion analysis panel

  • Used to detect large gene rearrangements or deletions/duplications in breast cancer-related genes, often complementing sequence analysis.

• 81435: Hereditary colon cancer disorders, genomic sequence analysis panel

  • Focuses on hereditary colon cancer genes; not typically used with 81434 but relevant in broader hereditary cancer testing workflows.

Codes 81211, 81213, 81432, and 81433 are commonly used together or as alternatives depending on the clinical scenario and the extent of genetic testing required.

National mean rates for CPT code 81434 among commercial payers (BUCA average: $469.24) are substantially higher than typical Medicare rates, which are not available in the input for comparison. Blue Cross Blue Shield ($502.43) and Cigna ($486.62) have the highest mean rates among the major commercial payers, while Aetna ($437.43) is the lowest.

Rate dispersion varies significantly across payers. Cigna exhibits the widest spread, with a difference of $495.00 between its 75th and 25th percentiles ($682.00 - $187.00), indicating substantial variability in contracted rates. Blue Cross Blue Shield also shows a broad range ($199.33), while Aetna ($199.00) and BUCA ($251.50) are somewhat tighter. UnitedHealth Group has a moderate spread of $291.26. The table and chart below present the full breakdown of national benchmarks for each payer.